EFMC
RIGL icon

Empire Financial Management Company’s Rigel Pharmaceuticals RIGL Stock Holding History

Empire Financial Management Company’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-45,445
Closed -$1.23M – 201
2026
Q1 		$1.23M Sell
45,445
-31,000
-41% -$1.04M 0.28% 98
2025
Q4 		$3.27M Sell
76,445
-13,066
-15% -$493K 0.71% 50
2025
Q3 		$2.54M Buy
89,511
+66,011
+281% +$1.97M 0.58% 57
2025
Q2 		$440K Hold
23,500
– – 0.13% 151
2025
Q1 		$423K Buy
23,500
+11,500
+96% +$233K 0.13% 149
2024
Q4 		$202K Sell
12,000
-2,250
-16% -$43.2K 0.06% 195
2024
Q3 		$231K Buy
+14,250
New +$168K 0.07% 188
2024
Q2 		– Sell
-30,450
Closed -$451K – 215
2024
Q1 		$451K Buy
30,450
+11,150
+58% +$150K 0.15% 147
2023
Q4 		$280K Buy
+19,300
New +$197K 0.11% 169

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Empire Financial Management Company's RIGL Position: Q2 2026 in Review

Empire Financial Management Company sold out of Rigel Pharmaceuticals (RIGL) in Q2 2026, closing a stake of 45,445 shares — an estimated $1.23M sold.

Empire Financial Management Company first reported a position in RIGL in Q4 2023 and held it in 9 quarters. The position peaked at $3.27M in Q4 2025. 155 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Empire Financial Management Company reported no remaining Rigel Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Empire Financial Management Company sold 45,445 Rigel Pharmaceuticals shares in Q2 2026, an estimated $1.23M.
  • Empire Financial Management Company first reported a position in Rigel Pharmaceuticals in Q4 2023 and held it in 9 quarters.
  • Empire Financial Management Company's Rigel Pharmaceuticals position peaked at $3.27M in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Empire Financial Management Company's 13F filing for Q2 2026, filed 14 Aug 2026.